ストックスクリーナーアプリを入手
246.40
1.30%
-3.25
アフターアワーズ：
246.40
前日終値:
$249.65
開ける：
$251.84
24時間の取引高:
228.73K
Relative Volume:
0.67
時価総額：
$5.46B
収益：
$2.58B
当期純損益:
$-778.69M
株価収益率:
-9.0157
EPS:
-27.33
ネットキャッシュフロー:
$223.75M
1週間 パフォーマンス:
-4.11%
1か月 パフォーマンス:
+6.21%
6か月 パフォーマンス:
-28.04%
1年 パフォーマンス:
-17.94%
1日の値動き範囲:
$244.62
$252.49
1週間の範囲:
$244.44
$255.57
52週間の値動き範囲:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
名前
Bio Rad Laboratories Inc
セクター
電話
(510) 724-7000
住所
1000 ALFRED NOBEL DRIVE, HERCULES
BIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
246.40 | 6.99B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
123.67 | 229.69B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.64 | 152.68B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
389.40 | 148.84B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.61 | 115.21B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.49 | 45.78B | 5.54B | 4.18B | 623.10M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
Is Bio Rad Laboratories Inc. a good long term investmentFast-track wealth growth - Autocar Professional
Bio Rad Laboratories Inc. Stock Analysis and ForecastPowerful growth strategies - PrintWeekIndia
How high can Bio Rad Laboratories Inc. stock price go in 2025Stable Stocks With High Yield - beatles.ru
What analysts say about Bio Rad Laboratories Inc. stockOutstanding yields - Jammu Links News
Future Industry Growth Of Real-Time Polymerase Chain Reaction - openPR.com
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025 - BioSpace
Biochip Market Global Outlook Report 2025, with Focus on Microarrays and Lab-on-a-Chip - GlobeNewswire Inc.
Unexpected Trends Reshaping the Cancer Biomarkers Market - openPR.com
Laboratory Mixer Market Gains Momentum with Automation - openPR.com
Trending Report on Liquid-Based Diagnostics Market 2025-2032 - openPR.com
Bioinformatics Market Exclusive Report with Detailed Study - openPR.com
Enzyme Linked Immunosorbent Assay Market Set to Expand Through - openPR.com
Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com
Single Cell Omics Market Size, Share, Industry Growth Report - openPR.com
Saudi Arabia In-Vitro Diagnostics Market Report 2025-2030 Featuring Abbott, BD, Bio-Rad Laboratories, Biomerieux, Danaher, Nihon Kohden, Roche, Siemens Healthineers, Sysmex, Thermo Fischer Scientific - Yahoo Finance
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms - Yahoo Finance
Protein Chip Market Booming as High-Throughput Proteomics - openPR.com
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - drugdiscoverynews.com
Bio-Rad expands Droplet Digital PCR offering through strategic acquisition and platform rollout - SelectScience
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shareholders Might Be Looking For Exit - 富途牛牛
Bio-Rad's Digital PCR Play: A Strategic Move to Dominate Genomics and Diagnostics - AInvest
Bio-Rad expands digital PCR portfolio with four new platforms By Investing.com - Investing.com Nigeria
Bio-Rad Labs announces launch of four new Droplet Digital PCR platforms - BioSpectrum India
Bio-Rad expands digital PCR portfolio with four new platforms - Investing.com
Single-cell Omics Market Projected To Witness Massive Growth, - openPR.com
Trend Tracker for (BIO.B) - news.stocktradersdaily.com
RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating - MarketScreener
Bio-Rad Completes Acquisition of Stilla Technologies - TipRanks
New Bioanalytical Antibodies from Bio-Rad Boost Assay Versatility - Lab Manager
Inside the Future of the RNA Extraction And Purification Market: - openPR.com
The Best Healthcare Stocks to Buy - Morningstar
Sequencing Consumables Market Deep Research with Forecast - openPR.com
Transfection Reagents and Equipment Market | Driving Gene - openPR.com
Global Gene Expression Analysis Market | RNA Sequencing & PCR - openPR.com
Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development - drugdiscoverynews.com
Bio-Rad extends anti-idiotypic antibody and SpyCatcher Reagent ranges for bioanalysis and antibody drug development - Cambridge Network
Global Gel Electrophoresis Equipment Market Surges Amid Rising - openPR.com
DNA Extraction Kits Market Future Business Opportunities - openPR.com
Protein Engineering Market Fueled by AI, Genomics, - openPR.com
Immunohistochemistry Market Trends | Cancer Diagnosis & - openPR.com
How to Take Advantage of moves in (BIO) - news.stocktradersdaily.com
Global Genomics Market Surges Toward USD 115.4 Billion - openPR.com
Genetic Testing Market Surges Amid Rising Demand - openPR.com
Robust Growth in Personalized Psychiatry Market (2025-2032): - openPR.com
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
0.28%
0.04%
大文字化:
|
ボリューム (24 時間):